Navigation Links
Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
Date:2/6/2009

CHARLOTTESVILLE, Va., Feb. 6 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs that enhance oxygen diffusion, today announced the completion of a $2.9 million private placement. The proceeds will support the company's overall growth and clinical programs for its lead drug compound, trans sodium crocetinate (TSC). In addition, David G. Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals, will be presenting at two industry conferences: BioBusiness 2009, February 16 - 18, in Geneva, Switzerland, and BioNetwork East 2009, March 16 - 18, in Naples, Florida.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090206/PH67853 )

To date, Diffusion Pharmaceuticals has raised $13.1 million in private equity and has received $2.6 million in government research and development funding from the Office of Naval Research (ONR), bringing the company's total funding to $15.7 million. This funding has enabled the Company to advance its drug-development programs, which include a multi-center Phase I/II clinical trial in peripheral arterial disease patients and a Phase I trial in patients with high-grade gliomas at Johns Hopkins University. These clinical trials are designated NCT00725881 and NCT00826930, respectively, on the clinicaltrials.gov Website.

"In an economic environment in which one third of all US biotech companies may go out of business for lack of funding, we are fortunate to have key investors who strongly believe in our technology and who continue to increase their investment level. We are also fortunate to have attracted several new investors at significant levels," said David G. Kale
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
2. Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled Bipolar Trans Carotenoid Salts and Their Uses, for Its Family of First-In-Class Molecules
3. Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced four new ... and provides a good start to Q4.  The orders are for ... and one in the Middle East . ... Peter Bruijns , President & CEO. "Total bidding activity and ... have been for any complete year since the company has tracked ...
(Date:10/20/2014)... October 20, 2014 OncLive® ... Kimmel Cancer Center at Thomas Jefferson University has ... Through the Strategic Alliance Partnership program, the Sidney ... collaborate to raise awareness of the Center’s cutting-edge ... other projects. Clinicians and other health care professionals ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The ... ABIM will take place at the Congress ... 2014 is now available at http://www.abim.ch ... and organizations from all over the globe ... the latest products and developments on the ...
(Date:10/19/2014)... The Asia-Pacific Speech Analytics market report ... with analysis and forecast of revenue. This market is ... $208 million by 2019, at a Compound Annual Growth ... Browse through the TOC of the Asia-Pacific Speech Analytics ... analysis provided. It also provides a glimpse of the ...
Breaking Biology Technology:Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4
... , PRINCETON, N.J., July 15 ... a license agreement with Merck KGaA, Darmstadt, Germany, providing the ... Technology platform for the research, development and commercialization of their ... , "We are extremely pleased ...
... July 14 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; ... and six months ended May 31, 2009. All dollar amounts ... At May 31, 2009, our cash and cash equivalents totaled ... Our net cash used in operating activities for the three ...
... , , , LAKE ... technology company focused on improving blood collection, separation, safety and ... agreement with Verax Biomedical Incorporated to market, sell and distribute ... used to detect bacterial contaminants in donated blood platelets. ...
Cached Biology Technology:BioWa Announces License of POTELLIGENT(R) Technology to Merck KGaA 2Vasogen Announces Second Quarter 2009 Results 2Vasogen Announces Second Quarter 2009 Results 3Vasogen Announces Second Quarter 2009 Results 4Vasogen Announces Second Quarter 2009 Results 5Vasogen Announces Second Quarter 2009 Results 6Vasogen Announces Second Quarter 2009 Results 7Vasogen Announces Second Quarter 2009 Results 8Vasogen Announces Second Quarter 2009 Results 9Vasogen Announces Second Quarter 2009 Results 10Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test 2Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test 3
(Date:10/14/2014)... – Scientists have sequenced the house fly genome for ... might expect from an insect that thrives in pathogen-rich ... Oct. 14 in the journal Genome Biology , ... and of how flies quickly adapt to resist insecticides, ... house flies (Musca domestica) carry and transmit more than ...
(Date:10/14/2014)... – October 14, 2014 – Scientists from The Scripps ... the National Institutes of Health (NIH) to lead an ... hemorrhagic fever disease in Africa. The study aims to ... some patients die, while others survive the inflection. ... the basic mechanism of how Lassa fever virus causes ...
(Date:10/14/2014)... October 14, 2014 – Over the past decades, we ... institutions to meet the needs of infants for social ... these infants to thrive. , Infancy and ... of the cortex. A generation of research suggests that ... cortical development and cognitive function. In contrast, deprivation and ...
Breaking Biology News(10 mins):House fly genome reveals expanded immune system 2Scripps Research Institute team receives $6.6 million to investigate deadly Lassa virus 2Institutional rearing may increase risk attention-deficit disorder 2
... a team led by researchers from Caltech has for ... of chemoreceptorsthe receptors that sense and respond to chemical ... specific architecture is the same throughout a wide variety ... stable, universal structure that has been conserved over evolutionary ...
... new university/industry network to pursue the development of biomaterials, ... increasing incidence of eye disease. The 20/20: NSERC ... as part of the Natural Sciences and Engineering Research ... Minister of State (Science and Technology) Gary Goodyear today ...
... cell researcher Treena Livingston Arinzeh will discuss current stem cell ... for bone fracture and osteoarthritis treatments, spinal cord repair, and ... The event will be held Sept. 29, 2009, at ... floor of the NJIT Campus Center. The ...
Cached Biology News:Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 2Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 3Caltech scientists get detailed glimpse of chemoreceptor architecture in bacterial cells 4New research network at McMaster aims to build a better eye 2
Request Info...
Designed for use with any of the Agencourt kits in tube format....
Collected from animals that are 16 to 18 months old. Sterile, Cell culture tested, ID clarifier: USA Origin...
... glass plates, bar clamp, and a built-in ... these units are:, safety interlock lids , ... upper and lower reservoirs have drains with ... of buffer solutions , leveling base with ...
Biology Products: